Medifast (NYSE:MED – Get Free Report) issued an update on its fourth quarter 2024 earnings guidance on Monday morning. The company provided EPS guidance of 0.100-0.650 for the period, compared to the consensus EPS estimate of -0.180. The company issued revenue guidance of $100.0 million-$120.0 million, compared to the consensus revenue estimate of $130.0 million.
Analyst Upgrades and Downgrades
Separately, DA Davidson raised Medifast from an “underperform” rating to a “neutral” rating and boosted their target price for the stock from $16.50 to $17.00 in a report on Tuesday.
Get Our Latest Analysis on MED
Medifast Stock Performance
Medifast (NYSE:MED – Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The specialty retailer reported $0.35 EPS for the quarter, beating the consensus estimate of ($0.15) by $0.50. The business had revenue of $140.16 million for the quarter, compared to the consensus estimate of $135.45 million. Medifast had a return on equity of 16.01% and a net margin of 1.09%. During the same quarter in the prior year, the business earned $2.12 earnings per share. Equities analysts anticipate that Medifast will post 1.12 earnings per share for the current fiscal year.
Medifast Company Profile
Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.
See Also
- Five stocks we like better than Medifast
- Investing in Travel Stocks Benefits
- What a Trump Win Looks Like for the Market Now and Into 2025
- Investing in the High PE Growth Stocks
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.